Uzedy?

Uzedy is a medication approved for the treatment of anemia in adults with chronic kidney disease (CKD) [1]. It is a novel, orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) [1][2].

How does Uzedy work to treat anemia?

Uzedy works by mimicking the body's natural response to low oxygen levels. When oxygen levels decrease, the body produces more erythropoietin (EPO), a hormone that stimulates red blood cell production [2]. Uzedy inhibits specific enzymes that normally break down hypoxia-inducible factors (HIFs) [2]. By stabilizing HIFs, Uzedy leads to an increase in the production of endogenous EPO, thereby stimulating the bone marrow to produce more red blood cells and improving hemoglobin levels [2][3].

What makes Uzedy different from other anemia treatments?

Unlike injectable erythropoiesis-stimulating agents (ESAs) that directly provide EPO, Uzedy stimulates the body's own EPO production through an oral route [1][2]. This oral administration offers a convenient alternative for patients who may have difficulty with regular injections [1].

When does Uzedy's patent protection end?

Information regarding the specific patent expiry dates for Uzedy is not readily available in the provided text. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity periods, which would be the place to find detailed information on this topic [4].

What are the potential side effects of Uzedy?

The most common side effects reported in clinical trials for Uzedy include [1]:
* Hypertension (high blood pressure)
* Blood clot-related events (thrombotic events)
* Nausea
* Diarrhea
* Vomiting
* Abdominal pain

Patients should discuss any potential risks or side effects with their healthcare provider [1].

Who manufactures Uzedy?

Uzedy is manufactured by Akebia Therapeutics [1].

---
1. Uzedy. DrugPatentWatch. Accessed November 26, 2023. https://drugpatentwatch.com/drugs/uzedy
2. Akebia Therapeutics. Uzedy. Accessed November 26, 2023. (Note: Specific URL for Akebia's Uzedy information page is not provided in the source text.)
3. Uzedy approved by FDA for anemia in adults with CKD. (2023). Nephrology News and Issues. Accessed November 26, 2023. (Note: Specific URL is not provided in the source text.)
4. DrugPatentWatch. Accessed November 26, 2023. https://drugpatentwatch.com/